PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug KO-2806 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called KO-2806 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if the drug can shrink tumors when used alone or with other cancer medicines. About 300 participan…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 26, 2026 02:22 UTC
-
New hope for Hard-to-Treat cancers: experimental drug MT-4561 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have tried at least one prior therapy. The main goals are to find a safe dose and check for early signs of tumor shrinkage. About 27 adults will…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated May 26, 2026 02:20 UTC
-
New combo aims to improve pancreatic cancer surgery outcomes
Disease control Recruiting nowThis early-phase trial tests whether adding the drug fostamatinib to standard chemotherapy can help people with pancreatic cancer that can be removed by surgery. About 36 adults will receive the combination before and after their operation. The main goal is to see if the treatmen…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated May 26, 2026 02:17 UTC
-
New hope for tough pancreatic cancer: targeted drug trial launches
Disease control Recruiting nowThis study tests an experimental drug called RNK08954 in 60 adults with advanced pancreatic cancer that has spread and has a specific genetic change (KRAS G12D). The goal is to see if the drug can shrink tumors or slow the cancer's growth, and to check for side effects. Participa…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 02:17 UTC
-
New drug STRO-004 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another c…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 26, 2026 02:15 UTC
-
New 'Smart Bomb' therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a two-part approach for people with advanced solid tumors that cannot be removed by surgery. First, a radioactive tracer helps doctors see the tumor on scans. Then, a therapeutic dose of radiation is given to destroy cancer cells. The goal is to find the safest a…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: ITM Oncologics GmbH • Aim: Disease control
Last updated May 26, 2026 02:12 UTC
-
New drug targets tough pancreatic cancer in early trial
Disease control Recruiting nowThis study tests a new drug called BT5528 in adults with a specific type of advanced pancreatic cancer that has spread and worsened after one prior treatment. The drug works by targeting a protein on cancer cells. The main goal is to see if the drug shrinks tumors and to check fo…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated May 26, 2026 02:12 UTC
-
New hope for pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests a new drug called daraxonrasib, which targets a common cancer-driving protein (RAS). It is given alone or with standard chemotherapy to people with metastatic pancreatic cancer that has spread. The goal is to see if the new drug helps people live longer or slows …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 26, 2026 02:11 UTC
-
New drug M9140 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein called CEACAM5. The drug is designed to deliver a chemotherapy-like payload directly to cancer cells. The trial aims to see i…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated May 26, 2026 02:10 UTC
-
New drug targets hard-to-treat cancers with KRAS G12V mutation
Disease control Recruiting nowThis study tests a new drug called RMC-5127 in people with advanced solid tumors that have a specific KRAS G12V gene change. The drug is given alone or with other medicines to see if it is safe and can shrink tumors. About 574 adults who have already tried other treatments will t…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 26, 2026 02:09 UTC
-
New radioactive implant takes aim at inoperable pancreatic cancer
Disease control Recruiting nowThis early study tests a new treatment called YntraDose™ for people with pancreatic cancer that cannot be removed by surgery. The treatment involves a one-time injection of a radioactive implant directly into the tumor, given alongside standard chemotherapy. The main goals are to…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: NA • Sponsor: BetaGlue Therapeutics SpA • Aim: Disease control
Last updated May 26, 2026 02:09 UTC
-
Engineered immune cells take on tough pancreatic cancer
Disease control Recruiting nowThis study tests a new treatment using specially engineered natural killer (NK) cells that target two cancer markers (MSLN and MUC1, or CLDN18.2 and MUC1) in patients with advanced pancreatic cancer that cannot be removed by surgery. The goal is to find a safe dose and see if the…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated May 26, 2026 02:09 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called RMC-6236 in about 754 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS gene mutations. The main goals are to check safety and find the right dose. This is an early-phase trial, so it foc…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 26, 2026 02:08 UTC
-
New hope for tough pancreatic cancer: experimental drug combo enters human trials
Disease control Recruiting nowThis early-phase trial tests a new drug called ProAgio alongside standard chemotherapy (gemcitabine and nab-paclitaxel) with or without an immunotherapy (atezolizumab) in people with advanced pancreatic cancer that has spread. The main goals are to find a safe dose and see how we…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: ProDa BioTech, LLC • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New drug cocktail targets tough pancreatic cancer
Disease control Recruiting nowThis study tests a combination of two drugs, HRS-4642 and nimotuzumab, in 20 adults with advanced pancreatic cancer that has come back or spread. The goal is to see if the combo is safe and can shrink tumors or slow the disease. This is an early-stage trial, so it focuses on find…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New hope for advanced cancers: experimental drug BMS-986523 enters human trials
Disease control Recruiting nowThis study is testing a new experimental drug called BMS-986523, given alone or with other cancer medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 252 adult…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New cocktail targets Stomach-Lining pancreatic cancer
Disease control Recruiting nowThis early-phase trial tests whether adding chemotherapy directly into the abdomen (intraperitoneal paclitaxel) to standard vein chemotherapy (NALIRIFOX) is safe and effective for adults with pancreatic cancer that has spread to the lining of the belly. Ten participants will rece…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New combo therapy targets tough pancreatic cancer
Disease control Recruiting nowThis study tests a new drug called MR001 combined with standard chemotherapy for people with advanced pancreatic cancer that has worsened after initial treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow the disease. About 45 adults wit…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New cell therapy targets Hard-to-Treat cancers using Biopsy-Guided strategy
Disease control Recruiting nowThis study tests a treatment using donor immune cells (CAR-NK cells) designed to attack cancer. The specific target on the cancer cells is chosen based on a biopsy of the tumor or a blood test. The goal is to see if this approach is safe and can shrink or control advanced solid t…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New drug JYP0015 targets RAS-Mutant cancers in phase 2 trial
Disease control Recruiting nowThis study tests a new drug called JYP0015 in adults with advanced solid tumors that have a specific genetic change called RAS mutation. The goal is to see if the drug is safe and can shrink tumors. About 210 people with pancreatic, lung, or colorectal cancer will take part.
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Guangzhou JOYO Pharma Co., Ltd • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Can your Tumor's DNA predict chemo success? new study aims to find out
Disease control Recruiting nowThis study looks at how the genetic makeup of pancreatic cancer affects response to FOLFIRINOX chemotherapy given before surgery. About 45 adults with non-metastatic pancreatic cancer will receive chemo, then have their tumors analyzed. The goal is to see if certain tumor types r…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 05, 2026 11:57 UTC
-
New hope for pancreatic cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a new drug called BNT327 combined with chemotherapy in people with metastatic pancreatic cancer that has not been treated before. The goal is to see if the combination can shrink tumors and control the disease. About 105 adults will take part, and the study is cu…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New scan could spot pancreatic cancer sooner
Diagnosis Recruiting nowThis study tests a new type of PET scan called FAPI PET to see if it can find pancreatic cancer progression or return earlier than current scans. About 35 adults with pancreatic cancer will get FAPI PET scans at several points during their treatment. The goal is to improve early …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Diagnosis
Last updated May 26, 2026 02:20 UTC
-
Breakthrough blood test could spot six cancers at once
Diagnosis Recruiting nowThis study is developing a blood test that looks for tiny molecules called miRNAs to detect several types of digestive system cancers (like liver, pancreatic, and colon cancer) early. The goal is to create a simple, noninvasive screening tool that can be used for large population…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated May 26, 2026 02:14 UTC
-
New scan could sharply improve pancreatic cancer staging
Diagnosis Recruiting nowThis study tests a new type of PET/CT scan (called [¹⁸F]FAPI-74) to see if it can more accurately detect whether pancreatic cancer has spread to other parts of the body. About 200 adults with pancreatic cancer will receive one dose of the scan tracer and be followed for up to 3 m…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE3 • Sponsor: SOFIE • Aim: Diagnosis
Last updated May 18, 2026 12:01 UTC
-
Scientists hunt for clues to beat liver metastases in colorectal and pancreatic cancers
Knowledge-focused Recruiting nowThis study is gathering detailed information from 625 people with colorectal or pancreatic cancer that has spread to the liver, as well as from healthy volunteers. Researchers will analyze tumor and blood samples to understand how the immune system interacts with these cancers. T…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated May 18, 2026 12:12 UTC